Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 3:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neovascular Age-related Macular Degeneration Clear all
Not listed No phase listed Observational
View directory record Official record
Conditions
Dry Macular Degeneration
Interventions
SS-OCT imaging
Device
Lead sponsor
Boston Image Reading Center
Industry
Eligibility
Not listed
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced May 22, 2026, 3:53 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
OPT-302, ranibizumab, sham intravitreal injection
Biological · Other
Lead sponsor
Opthea Limited
Industry
Eligibility
50 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
55
States / cities
Phoenix, Arizona • Beverly Hills, California • Encino, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced May 22, 2026, 3:53 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusions
Interventions
LKA651, Sham Comparator
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Pasadena, California • Fort Myers, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced May 22, 2026, 3:53 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
SB11 (Proposed ranibizumab biosimilar), Lucentis (ranibizumab)
Drug
Lead sponsor
Samsung Bioepis Co., Ltd.
Industry
Eligibility
50 Years and older
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
19
States / cities
Poway, California • Colorado Springs, Colorado • Fort Myers, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced May 22, 2026, 3:53 AM EDT
Not listed Phase 4 Interventional
View directory record Official record
Conditions
Age Related Macular Degeneration, Pigment Epithelial Detachment
Interventions
Aflibercept
Drug
Lead sponsor
Tennessee Retina
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
San Francisco, California • Lexington, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced May 22, 2026, 3:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Age-related Macular Degeneration, Choroidal Neovascular Age-related Macular Degeneration
Interventions
Not listed
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
60 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2014 · Synced May 22, 2026, 3:53 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Neovascular Age Related Macular Degeneration
Interventions
VEGF Trap, VEGF Trap
Drug · Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
6
States / cities
Fort Myers, Florida • Wichita, Kansas • Hagerstown, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2011 · Synced May 22, 2026, 3:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
CLS-AX, Anti-VEGF
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
50 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Bakersfield, California • Mountain View, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2023 · Synced May 22, 2026, 3:53 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Exudative Age-related Macular Degeneration
Interventions
RBM-007
Drug
Lead sponsor
Ribomic USA Inc
Industry
Eligibility
55 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
Phoenix, Arizona • Sacramento, California • Walnut Creek, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced May 22, 2026, 3:53 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Ranibizumab 0.5mg, Aflibercept 2.0mg
Drug
Lead sponsor
Arshad Khanani
Other
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced May 22, 2026, 3:53 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Iptacopan (LNP023), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 100 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
22
States / cities
Fullerton, California • Huntington Beach, California • Rancho Cordova, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced May 22, 2026, 3:53 AM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Macular Edema
Interventions
AIV007
Drug
Lead sponsor
AiViva BioPharma, Inc.
Industry
Eligibility
21 Years to 90 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Beverly Hills, California • Santa Ana, California • Eugene, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced May 22, 2026, 3:53 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Macular Edema, Macular Degeneration
Interventions
Ranibizumab
Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 9, 2019 · Synced May 22, 2026, 3:53 AM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD)
Interventions
AXT107 0.1 mg, AXT107 0.25 mg, AXT107 0.5 mg
Drug
Lead sponsor
AsclepiX Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Gilbert, Arizona • Los Angeles, California • St. Petersburg, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced May 22, 2026, 3:53 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
PDS Implant with Ranibizumab 100 mg/mL
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
81
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced May 22, 2026, 3:53 AM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
KH631
Drug
Lead sponsor
Chengdu Origen Biotechnology Co., Ltd.
Industry
Eligibility
50 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Phoenix, Arizona • Lemont, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced May 22, 2026, 3:53 AM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Wet Age-related Macular Degeneration
Interventions
Tarcocimab tedromer, Tabirafusp tedromer, Aflibercept
Drug
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
50 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
71
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced May 22, 2026, 3:53 AM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Squalamine Lactate Ophthalmic Solution, 0.2%, Placebo Ophthalmic Solution, ranibizumab
Drug
Lead sponsor
Ohr Pharmaceutical Inc.
Industry
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Beverly Hills, California • Hagerstown, Maryland • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced May 22, 2026, 3:53 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)
Genetic
Lead sponsor
Olix Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
Santa Maria, California • Oak Forest, Illinois • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced May 22, 2026, 3:53 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Macular Degeneration
Interventions
ranibizumab, aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
1,217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
176
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 144 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2012 · Synced May 22, 2026, 3:53 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Macular Degeneration
Interventions
Abicipar pegol
Drug
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
18
States / cities
Gilbert, Arizona • Arcadia, California • Beverly Hills, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced May 22, 2026, 3:53 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Macular Degeneration
Interventions
Pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
7
States / cities
Beverly Hills, California • Sacramento, California • Winter Haven, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced May 22, 2026, 3:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Exudative Macular Degeneration
Interventions
X-82 oral, ranibizumab (Lucentis)
Drug
Lead sponsor
Tyrogenex
Industry
Eligibility
50 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Beverly Hills, California • New London, Connecticut • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced May 22, 2026, 3:53 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Macular Degeneration
Interventions
Pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
16
States / cities
Tucson, Arizona • Beverly Hills, California • Pasadena, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2017 · Synced May 22, 2026, 3:53 AM EDT